未登录

W

Wenfen Fu

fujian medical university

H指数:6

被引数:89

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Does T1c-2N0-1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Discovery of proliferation essential gene signature and ACTL6A as potential biomarker for predicting prognosis and neoadjuvant therapy response in triple-positive breast cancer

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Clinical significance and immune landscape analyses of the immune related genes based prognostic signature for HER2 positive breast cancer

CANCER RESEARCH

IF16.6

2024-05-020

PRE

Discovery of a proliferation essential gene signature and actin-like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple-positive breast cancer

IF5.1

2024-02-152

OAAI

The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

IF3.4

2024-01-020

OAAI

An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer

铁代谢和免疫相关基因标记预测三阴性乳腺癌的临床结局和分子特征

IF3.4

2022-06-077

OAAI

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy

T1aN0M0三阴性乳腺癌辅助化疗的生存结局

FRONTIERS IN ONCOLOGY

IF3.3

2020-09-305

OAAI

Different Clinicopathological Characteristics and Prognostic Factors for Occult and Non-occult Breast Cancer: Analysis of the SEER Database

FRONTIERS IN ONCOLOGY

IF3.3

2020-08-1914

OAAI